Type II collagen (CII) protein is the main component of hyaline cartilage. The clinical importance of CII in arthritis, aging, and osteoarthritis is significant, but its ability to induce specific immune tolerance has not been extensively studied previously. We have recently proven that CII is capable of inducing Anterior Chamber Associated Immune Deviation (ACAID) when injected into the eye.
The eye is vulnerable to severe inflammatory immune responses that could cause serious damage. Thus, regulatory mechanisms are in place to protect against intra-ocular inflammation. Anterior chamber-associated immune deviation (ACAID) is one such mechanism whereby the antigenic entry into the AC induces potent antigen-specific immune tolerance that is not only localized in the eye but also extends to the periphery. In order to obtain this potent antigen-specific peripheral immune tolerance, ACAID involves intricate multicellular communications between the eye-derived F4/80+ antigen presenting cells (APCs), splenic T cells, marginal zone B cells, NKT cells, and yo T cells (l). ACAID is characterized by the negative regulation of systemic Th 1 responses and of delayed type hypersensitivity (DTH) responses (2) . This is achieved through professional APCs that induce the generation of afferent and efferent T regulatory cells (Tregs) (3) , which could potentially be used to curb T-helper cell responses in autoimmune diseases. Professional APCs can be immunogenic or tolerogenic depending on the involvement of unique cytokines that impact their maturation and activation, such as the immunosuppressive cytokines IL-I 0 and TGF-~that push towards the tolerogenic type (4, 5) . The in vitro culture of F4/80+ macrophages with antigens in the presence ofTGF-~2 could lead to the generation of ocular-like ACAID APCs, that induce antigen-specific immune tolerance when injected into experimental mice (2, 6) .
Type II collagen (CII) protein is the main component of hyaline cartilage. Degeneration of CII has also been associated with aging and osteoarthritis (7) . The clinical significance of CII in rheumatoid arthritis is established (8) . We have recently shown that CII induced peripheral tolerance when injected into the AC of the eye of Balblc mice (9) . Due to the reported functional similarities of in vitro-generated ocular-like ACAID APCs and eye-derived APCs (10, 11) , we hypothesized that in vitro-generated ACAID macrophages that are specific to CII could induce CII-specific immune tolerance, similar to what we reported previously with the AC injection of CII (9) . Following the intravenous injection of CIIspecific ACAID APCs and Cll-specific Tregs into Balblc mice, we tested for ACAID generation and examined the regulatory functions of whole spleen cells, T cells, CD4+ CD25+ T cells, and CD8+ T cells. This is the first study to report the in vitro generation of Cll-specific ACAID-mediated tolerance in Balblc mice.
MATERIALS AND METHODS

Mice
BALB/c mice (6-8 weeks of age) were obtained from Jackson Laboratories (Bar Harbor, ME, USA). All animals were maintained in the animal care facility of the Eugene Applebaum College of Pharmacy and Health Sciences. Animal experiments were conducted according to the guidelines of the Institutional Animal Care and Use Committee (IACUC), Wayne State University.
Generation ofACAJD APCs
ACAID APCs were generated in vitro as described previously (2, 6) . Ocular-like APCs from Balb/c mice were generated as described before (12) . Briefly, APCs were cultured overnight (2 xl 0 6 cells/ml) in cRPMI 1640 with 10 mg/ml CII and 2-5 ng/ml TGF-p2 (R&D Systems) at concentrations similar to those present in the aqueous humor of the eye (12) .
In vitro generation ofACAID Tregs
We used an in vitro spleen cell culture system that we had previously used to generate Tregs that express the same properties and surface markers as Tregs produced in vivo (2, 6) . ACAID APCs (5x 10 6 ) , specific to CII, were added to a 100 mm petri dish containing 5x 10 7 spleen cells harvested from normal Balb/c mice and the culture was incubated for 5-7 days at 37°C before testing for the presence ofTregs.
Immunization by subcutaneous injection
Mice immunization was performed by subcutaneous injection of 250 ug of CII (Sigma-Aldrich) that was emulsified 1:1 in complete Freund's adjuvant (CFA; Sigma-Aldrich). Each animal received 200 ul of the CIII CFA emulsion.
DTH assay
We performed DTH assays in a similar manner to that which had been carried out previously (9) . Briefly, 200 ug of CII in 20 ul was injected intradennally into the left ear pinna, and 20 ul 10 mM acetic acid was injected into the right ear pinna (internal control). DTH assays were performed seven days after the subcutaneous immunization with CIIICFA. The ear swelling measurements were performed using a Mitutoyo engineer's micrometer before and 24 h after CII injection. The results were measured as: specific ear swelling = (24h measurement -Oh measurement) for left ear -(24-h measurement -Oh measurement) for right ear. Results after 48 h are calculated in a similar manner: specific ear swelling = (48-h measurement -Oh measurement) for left ear -(48-h measurement -Oh measurement) for right ear.
In vivo generation ofACAID Tregs
Generation of splenic Tregs in vivo was carried out as before (9) . Briefly, mice were subcutaneously immunized with 250 ug CII in CFA (1:1) seven days after the ACAID Cll-specific APCs injection via the intravenous route. Spleen cells were harvested on day 14 and were used for the LAT assay (described below). In other experiments, CD90.2+ or CD8+ expressing cells were isolated from the whole spleen cell population by incubating ACAID spleen cells with CD90.2 or CD8 microBeads (10~l per 10 7 cells) (Miltenyi Biotec Inc., CA, USA) for 15 min at 4-8°C. The cells were subsequently washed twice by centrifugation, and the cell suspension was loaded on an LS MACS column placed on a MACS separator. In other experiments, CD4+CD25+ Regulatory T Cell Isolation Kit were used to isolate CD4+CD25+ cells from the spleen cell population.
Local adoptive transfer (LAT) assay
We have described details of the LAT assay previously (2, 6, 9) . Briefly, the putative Tregs were injected (1x 10 6 cells in 10 ul) with spleen cells (1x 10 6 cells in 10 ul) collected from subcutaneously immunized donors and 200 ug CII into the left ear pinnae of a naive mouse. The presence of Tregs was confirmed by the inhibition of the ear swelling responses induced by immune spleen cells after 24 hand 48 h.
(i) LAT assay on spleen cells isolated from mice injected with CII-specific ACAID APC: Balb/c mice were injected with Cll-specific ACAID APCs via the IV route on day O. After immunization with CIIICFA on day 7, putative regulatory spleen cells were harvested on day 14 and were tested for their regulatory properties in a LAT assay in which equal numbers ofwhole spleen cells (lx10 6 cells) from ACAID mice were combined with effector spleen cells (harvested from Cll-immunized mice) and
cn. The suspension (20 ul) was injected directly into the left ear pinna of naive mice. There were two positive control groups: a specificity control that was exactly the same except for using ovalbumin (OVA)-specific ACAID APCs instead of Cll-specific cells. In the other positive control group, naive mice ears received a mixture of Cll-immunized spleen cells and naive spleen cells along with cn. There were two negative control groups: mice that received only naive spleen cells along with Cll and those that received cn alone (no cells). We monitored the changes in ear swelling responses (after 24 hand 48 h).
(ii) LAT assay on splenic T cells from mice injected with Cll-specific ACAID APC: The CD90.2+ splenic T cell population was isolated from the whole putative regulatory cell population using CD90.2 microBeads. A LATassay was performed as described above with similar control groups.
(iii) LAT assay on CD8+ splenic T cells from mice injected with Cll-specific ACAID APC: The CD8+splenic T-cell population was isolated from the whole putative regulatory cell population of the spleen using CD8+ microBeads. A LAT assay was performed as described above with similar control groups.
(iv) LAT assay on CD4+CD25+ splenic T cells from mice injected with Cll-specific ACAID APC: The CD4+ CD25+ splenic T-cell population was isolated from the whole putative regulatory cell population of the spleen using CD4+ CD25+ Regulatory T-Cell Isolation Kit. A LAT assay was performed as described above with similar control groups.
Statistics
Statistical significance was determined using Student's t-test.
RESULTS
In vitro generated ACAID APCs inhibit DTH responses
To examine the hypothesis that in vitro-generated CII-specific ACAID APCs induce peripheral tolerance in Balb/c mice, we adoptively transferred ACAID APCs into naive Balb/c mice on day O. The recipient mice were subcutaneously immunized with CII emulsified with CFA on day 7. On day 14, the mice were challenged with CII by intradermal injections in the ear. We found that tail vein injection of Cll-specific ACAID APC did induce immune tolerance in the ACAID-induced mice, which was evident from the significant suppression of DTH responses observed in these mice as compared to the positive control mice that did not receive ACAID APCs (Fig. 1) .
In vitro-generated ACAID Tregs inhibit DTH responses
We previously showed that AC injection of CII leads to the generation of Tregs capable of suppressing DTH responses (9) . Here, we tested whether the in vitro-generated Cll-specific ACAID APCs have the ability to induce Cll-specific Tregs in vitro by co-culturing these ACAID APCs with spleen cells isolated from naive mice. After 5-7 days, we examined for the presence of putative Tregs using a LAT assay. Spleen cells were isolated from naive and CIVCFA-immunized mice. Approximately, lx l O" Cll-specific putative Tregs were mixed with an equal number of immune spleen cells (containing effector cell populations harvested from Cll-immunized mice) and CII (200 ug). The suspension (20 Ill) was inoculated through intradermal injection into the left ear pinna of naive Balb/c mice, and the same volume of 10 mM acetic acid was injected into the right ear pinna as an internal control. A positive control was included that received Cll-immunized spleen cells and narve spleen cells with CII. The negative control received only narve spleen cells (2xl0 6 cells) along with CII. Results indicated that the recipients of in vitro-generated CII-specific Tregs demonstrated impaired DTH responses to CII as compared to the positive control cells, *P=0.0068 ( 
Fig. 3. Spleen cells from Balble mice injected with ClI-specific ACAID APCs display regulatory activities (LAT assay). CII-specific ACAID APCs were injected into Balb/c mice on day 0followed by subcutaneous immunization with CIIICFA on day 7 and a LAT assay was conducted on whole spleen cells on day 14 in which equal numbers ofwhole spleen cells (l xl O" cells) from ACAID mice were combined with effector spleen cells (harvestedfrom CII-immunized mice) and CII. The suspension (20 pl) was injected directly into the left ear pinna ofnaive mice. There were two positive control groups: one in which ovalbumin (OVA)-specific ACAID APCs were used instead ofCll-specific cells and one in which naive mice ears received a mixture of Cll-immunized spleen cells and naive spleen cells along with CII. There were two negative control groups: mice that received only naive spleen cells along with CII and those that received CII alone (no cells). The regulatory activity ofspleen cells was confirmed by the inhibition ofear-swelling responses ofimmune spleen cells after 24 h (panel a) and 48 h (panel b).
(48 h). As expected, the negative control group showed negative ear swelling responses (Fig. 2) .
In vivo generated ACAID Tregs inhibit DTH responses
We recently demonstrated that the AC injection with CII led to the generation of splenic regulatory cells (9) . In this study, we performed LAT assays to determine whether the IV injection with CII-specific ACAID APCs led to the generation of splenic regulatory cells.
(i) LAT assay on spleen cells isolated from mice injected with Cll-specific ACAID APC: The putative regulatory cells induced significant inhibition of ear swelling responses as compared to the positive control groups (Fig. 3) . The statistical significance for ear swelling measurements obtained were as follows: ACAID mice vs positive control (no regulatory spleen cells), *P=O.OOOI (24 h); *P=O.00003 (48 h). ACAID mice vs positive control (OVA-specific regulatory spleen cells), *P=O.00005 (24 h); *P=O.00004 (48 h). As expected, there were no significant ear swelling responses observed in either of the negative control groups (Fig. 3) .
(ii) LATassay on splenic T cellsfrom mice injected with CIJ-specific ACAID APC: Splenic T cells inhibited ear swelling responses as compared to the positive controls (Fig. 4) . The statistical significance for ear swelling measurements was as follows: ACAID mice vs positive control (no regulatory splenocytes), *P=O.OOOOOI (24 h); *P=O.00036 (48 h). ACAID mice vs positive control (OVA-specific regulatory splenocytes), *P=O.0002 (24 h); *P=O.00007 (48 h). We and others have demonstrated roles for CD8+ ACAID Tregs in regulating the expression of immune responses (1, 13, 14) . Thus, we hypothesized that CD8+efferent Tregs in spleen are solely responsible for regulating DTH responses in this in vitro-induced Cll-specific ACAID model. This led us to the following LAT assay. 
Fig. 4. Splenic T cells from Balble mice injected with ClI-specific ACAID APCs display regulatory activities (LAT assay).
CIJ-specific ACAID APCs were injected into Balble mice on day 0followed by subcutaneous immunization with ClIlCFA on day 7 and a LAT assay was conducted on splenic T cells (isolatedfrom the spleen using CD90.2 microlleads) on day 14 as described above. There were two positive control groups: one in which ovalbumin (OVA)-specific ACAJD APCs were used instead ofClI-specific cells and one in which naive mice ears received a mixture ofCll-immunized spleen cells and naive spleen cells along with ClI. There were two negative control groups: mice that received only naive spleen cells along
with ClI and those that received ClI alone (no cells). The regulatory activity ofsplenic T cells was confirmed by the inhibition ofear-swelling responses ofimmune spleen cells after 24 h (panel a) and 48 h (panel b).
(iii) LAT assay on CD8+ splenic T cells from mice injected with Cll-specific ACAID APC: Splenic CD8+ T cells inhibited ear swelling responses as compared to the positive controls (Fig. 5) . The statistical significance for ear swelling measurements was as follows: ACAID mice vs positive control (no regulatory splenocytes), *P=O.000005 (24 h); *P=O.00008 (48 h). ACAID mice vs positive control (OVA-specific regulatory splenocytes), *P=O.OOO 16 (24 h); *P=O.00006 (48 h).
(iv) LATassay on CD4+CD25+ splenic Tcellsfrom mice injected with Cll-specific ACAID APC: Splenic CD4+CD25+ T cells failed to inhibit ear swelling responses as compared to the positive controls (Fig.  6 ). This excludes the possibility of a role for CD4+ CD25+ cells in directly regulating DTH responses in this in vitro-induced CII-specific ACAID model.
DISCUSSION
Antigen entry into the eye induces specific cell-mediated immune (CMI) tolerance to the ACintroduced antigens (1, 15). This eye-mediated peripheral tolerance is mainly achieved by complex cellular interaction processes involving the eyederived macrophages, activation of thymic NKT cells, marginal zone B cells, y8 T cells, and NK T cells, and the differentiation of antigen-specific CD4+ Tregs and CD8+ Tregs (1, 15). ACAID APCs functionally resemble the eye-derived APCs, and are believed to induce T-cell regulation (10, 11) . ACAID T-cell regulation mediated via CD4+ and CD8+ Tregs could be tested by monitoring DTH responses in experimental mice (2, 6) . Thus, we examined the ability of in vitro-generated CIIspecific ACAID APCs to promote the induction of peripheral tolerance.
The processes of inducing ACAID whether via the in vivo direct antigen injection into the AC or via the adoptive transfer of in vitro-generated ACAID APCs are different but lead to similar outcomes (3 Fig. 5 . Splenic CD8+ T cells from Balble mice injected with CII-specific ACAID APCs display regulatory activities (LAT assay). CII-specific ACAID APCs were injected into Balble mice on day 0followed by subcutaneous immunization with CIIICFA on day 7 and a LAT assay was conducted on splenic CD8" T cells (isolated from the spleen using CD8+ microBeads) on day 14 as described above. There were two positive control groups: one in which ovalbumin (OVA)specific ACAID APCs were used instead of CII-specific cells and one in which naive mice ears received a mixture of CII-immunized spleen cells and naive spleen cells along with CII. There were two negative control groups: mice that received only nai"ve spleen cells along with CII and those that received CII alone ( 
no cells). The regulatory activity of splenic CD8+ T cells was confirmed by the inhibition ofear-swelling responses ofimmune spleen cells after 24 h (panel a) and 48 h (panel b).
involves the complex interplay of several cytokines such as IL-IO (16) and TGF-p (4), and immune cell populations such as B cells (6), yo T cells (2), and NKT cells (17) . Experimental lines of evidence suggest that TGF-p plays a key role in the generation of Tregs in ACAID (14, 18) . Incubation of anti-TGF-p mAb with peritoneal exudate cells (PECs) prevents its ability to induce tolerance or generation of CD8+Tregs in recipients (4). IL-10 is known to be involved in TGF-p activation, and can induce TGF-p secretion by Tregs in trinitrobenzene sulfonic acid (TNBS)-induced experimental colitis (19) . Contrary to ACAID induced viaAC injection,ACAID induced via in vitro-generated ACAID APCs may require IL-4 (20) . Both in vitro and in vivo-induced ACAIDs are characterized by a lack of IFN-y production (20) . Although the generation of CD8+ Tregs occurs independently of IFN-y, their suppressive activity may require IFN-y for receptor stimulation (21) .
The potential therapeutic application of CD4+ and CD8+ Tregs have been demonstrated by a number of studies on autoimmune diseases (22) (23) (24) , transplantation (25) and inflammatory diseases (26) . ACAID has also been shown to significantly suppress the induction of experimental uveoretinitis (27) . Tolerogenic ACAID APCs could be used as potent therapeutic tools in a number of autoimmune disease models due to their antigen-specific suppressive activities that can regulate the selfantigen-specific T-cell responses. This present study shows that in vitro-generated CII-specific ACAID APC could potentially induce the generation of CII-specific CD8+ Tregs, which could impair ClIspecific immune responses, as confirmed by DTH and LAT assays. ClI-specific CD8+Tregs play crucial functions in the regulation of in vitro-generated immune tolerance at the efferent arm of regulation of the immune response (14, 26, 28) . On the other hand, ClI-specific CD4+ CD25+ Tregs were found to be dispensable at the efferent arm of regulation of Fig. 6 . Splenic CD4+ CD2s+ T cells from Balblc mice injected with Cll-specific ACAlD APCs did not display regulatory activities (LAT assay). Cll-specific ACAlD APCs were injected into Balble mice on day 0 followed by subcutaneous immunization with CIlICFA on day 7 and a LAT assay was conducted on splenic CD4+ CD25+ T cells (isolatedfrom the spleen using CD4+ CD2s+Regulatory T Cell Isolation Kit) on day J4 as described above. The splenic CD4+ CD25+ T cells did not display regulatory activities as confirmed by the lack of inhibition of ear-swelling responses of immune spleen cells after 24 the immune response. Based on this study and results shown in Fig. 2 , we propose the use of antigenspecific ACAID CD8+ Tregs in the management of autoimmune diseases. It remains to be elucidated whether different antigens could drive similar in vivo immune-deviation responses in autoimmune disease animal models. We have recently demonstrated that ACAID could be successfully induced via AC inoculation with CII, and that CD8+ efferent Tregs could solely mediate peripheral tolerance induction in these mice (9) . In the current study, we report the success of establishing an in vitro-mediated mode of induction of ACAID that is specific to the CII antigen. This successful. induction led to the generation of CII-specific tolerogenic APCs and CII-specific CD8+ Tregs that could induce ACAID in a potent manner. The suppressive responses were specifically mediated by CD8+ Tregs and not the CD4+CD25+T cell population.
